For help on how to get the results you want, see our search tips.
21 results
Keyword Remove keyword
Categories
Human Remove Human filter
-
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: Opinion provided by Committee for Medicinal Products for Human Use, opinion/position date: 14/11/2019, Last updated: 15/11/2019 -
List item
Referral: Xeljanz
tofacitinib, associated names: Xeljanz, Article 20 procedures
Status: Opinion provided by Committee for Medicinal Products for Human Use, opinion/position date: 14/11/2019, Last updated: 15/11/2019 -
List item
Referral: Zinbryta
daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, EC decision date: 27/03/2018, -
List item
Referral: Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard
Cervarix : Bivalent HPV vaccine (types 16, 18) -Gardasil : quadrivalent HPV vaccine (types 6, 11, 16, 18)Gardasil 9 : 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)Silgard : quadrivalent HPV vaccine (types 6, 11, 16, 18), associated names: Cervarix, Gardasil, Gardasil 9, Silgard, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/11/2015, EC decision date: 12/01/2016, Last updated: 20/01/2016 -
List item
Referral: Corlentor and Procoralan
ivabradine, associated names: Corlentor and Procoralan, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/11/2014, EC decision date: 15/01/2015, Last updated: 16/02/2015 -
List item
Referral: Esmya
ulipristal acetate, associated names: Esmya, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/05/2018, EC decision date: 26/07/2018, -
List item
Referral: Tysabri
natalizumab, associated names: Tysabri, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 25/04/2016, Last updated: 12/05/2016 -
List item
Referral: Zinbryta
daclizumab, associated names: Zinbryta, Article 20 procedures
Status: European Commission final decision, opinion/position date: 09/11/2017, EC decision date: 08/01/2018, Last updated: 12/01/2018 -
List item
Referral: Protelos and Osseor
strontium ranelate, Article 20 procedures
Status: European Commission final decision, opinion/position date: 20/02/2014, EC decision date: 15/04/2014, -
List item
Referral: Iclusig
ponatinib, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/10/2014, EC decision date: 15/01/2015, -
List item
Referral: Kogenate Bayer and Helixate NexGen
octocog alfa, Article 20 procedures
Status: European Commission final decision, opinion/position date: 19/12/2013, EC decision date: 20/02/2014, -
List item
Referral: Tredaptive, Pelzont and Trevaclyn
laropiprant / nicotinic acid, Article 20 procedures
Status: European Commission final decision, EC decision date: 22/03/2013, -
List item
Referral: Inductos
dibotermin alfa, associated names: Inductos, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/10/2015, EC decision date: 20/11/2015, -
List item
Referral: Maci
matrix-applied characterised autologous cultured chondrocytes, associated names: Maci, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/09/2014, EC decision date: 19/11/2014, -
List item
Referral: Xofigo
radium Ra223 dichloride, associated names: Xofigo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 26/07/2018, EC decision date: 28/09/2018, -
List item
Referral: SGLT2 inhibitors (previously canagliflozin)
canagliflozin, empagliflozin, dapagliflozin, canagliflozin / metformin, empagliflozin / metformin, dapagliflozin / metformin, associated names: Xigduo, Ebymect, Edistride, Synjardy, Forxiga, Jardiance, Vokanamet, Invokana, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/02/2017, EC decision date: 04/05/2017, -
List item
Referral: SGLT2 inhibitors
canagliflozin, dapagliflozin,empagliflozin, associated names: Edistride, Ebymect, Xigduo, Vokanamet, Synjardy, Jardiance, Invokana, Forxiga, Article 20 procedures
Status: European Commission final decision, opinion/position date: 25/02/2016, EC decision date: 28/04/2016, -
List item
Referral: Lartruvo
olaratumab, associated names: Lartruvo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/01/2019, EC decision date: 19/07/2019, Last updated: 22/08/2019 -
List item
Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)
daclatasvir / dasabuvir / sofosbuvir / ledipasvir / simeprevir / ombitasvir/paritaprevir / ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017 -
List item
Referral: Picato (updated)
ingenol mebutate, associated names: Picato, Article 20 procedures
Status: Under evaluation, Last updated: 21/01/2020 -
List item
Referral: Zydelig
idelalisib, associated names: Zydelig, Article 20 procedures
Status: European Commission final decision, opinion/position date: 21/07/2016, EC decision date: 15/09/2016, Last updated: 03/10/2016